ISPOR West China Chapter Annual Report 2014

TO:
Board of Directors
International Society for Pharmacoeconomics and Outcomes Research
505 Lawrence Square Blvd South
Lawrenceville, NJ 08648 USA

PREPARED BY:
Xin Sun, PhD
Professor
Chinese Evidence-Based Medicine Center
West China Hospital
Sichuan University
Chengdu, China

Background:

The ISPOR West China Chapter was approved in Feb 2014. The chapter has 40 members. The current leadership of the ISPOR West China Chapter is comprised of the following:

President | Xin Sun, PhD
---|---
Professor
Chengdu, China

Secretary | Chuan Yu, PhD
---|---
Research Associate
Chengdu, China

Treasurer | Jing Tan, Msc
---|---
Lecturer
Chengdu, China

For more information on the ISPOR West China Chapter, please visit the ISPOR Regional Chapter website at http://www.isPOR.org/RegionalChapters/Chapter/West China.

**ISPOR West China Chapter Annual Report 2014**

<table>
<thead>
<tr>
<th>Activities / Accomplishments</th>
<th>Summary</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Scientific / Educational Activities</strong></td>
<td>The inaugural meeting of the ISPOR West Chapter was held on December 26, 2014. In conjunction with the chapter meeting, we organized the West China Forum for Post-marketing Drug Evaluation and Policy, as a major scientific and educational event for the chapter members and non-members. This Forum was developed based on the strengths in the field of drug evaluation and policy of the Chinese Evidence-based Medicine Center that was achieved in the past two decades. We decided to combine this event with the chapter’s inaugural meeting to expand the influence of the West China Chapter. This Forum included 14 seminars that were conducted by experts from the health authorities and academic institutions across China, summarizing the present status, challenges, and potential strategies for the assessment and policy making on post-marketing drugs. An official from National Center for Adverse Drug Reaction Monitoring was invited to give a plenary presentation on national post-marketing drug evaluation and policy. He gave the overview of the national reevaluation of drugs, and the importance and development of ADR monitoring. Professor Shanlian Hu from Fudan University presented on the development of pharmacoeconomics, focusing on the value of drug and the personalized medicine. Besides these two key speakers, there were over 10 other presenters from medical institutions and local center for adverse drug reaction monitoring. They shared their opinions and experiences on different topics, which included the evidence-based medicine and drug policy, drug outcomes research, local experience on adverse drug reaction monitoring, the post-marketing drug evaluation, drug use in special populations, and the practice of pharmacy administration. These seminars attracted the attendees from the academic institutions, clinical practice, health authorities, pharmaceutical industries, and other organizations around China. They gave warm and enthusiastic feedbacks to the seminars and looked forward to the next seminars.</td>
</tr>
<tr>
<td><strong>Policy-Related Activities</strong></td>
<td>In 2014, we have worked, in collaboration with 6 other academic institutions around China, on health technology assessment programs under the support and direction of the Chinese Ministry of Health. This program – funded by the Chinese Ministry of Health – will provide rigorous research evidence to support the decision on the inclusion and use of Hi-tech devices and advanced medical technologies in the medical institutions.</td>
</tr>
<tr>
<td><strong>Conferences and/or Chapter Meetings</strong></td>
<td>The first chapter meeting was held in Chengdu on 26 December 2014. As the inaugural meeting of West China Chapter, the core members of the chapter – who are typically lead researchers and administrative persons – were invited. There were 40 core members from 19 provinces, municipalities and autonomous regions of China.</td>
</tr>
</tbody>
</table>
During the meeting, Professor Xin Sun, the president of the chapter, introduced ISPOR and the West China Chapter to the attendees. The core members had a discussion on the chapter constitution, membership construction and the future development of West China Chapter and achieved agreement at the end of meeting.

It was decided that the chapter meeting of core members should be held annually and the meeting will be held in June each year. The members also agreed that the regular (non-core) members were also important to the development of the chapter. It is essential to develop regular members and have them registered. The establishment of interest groups – which would adapt a similar structure to the ISPOR – is another principal agreement of the meeting. These groups would help integrate the research resources in the region and develop cross-regional and interdisciplinary collaboration. The interest groups will be open for all the core members and regular members.

The members agreed that the President-Elect should be elected in the second annual meeting, instead of this meeting, so that the chapter members had the opportunity and time to select a person who is most appropriate for this position. Thus, the Chapter decided that the President-Elect and conveners of the interest groups selected at the second Chapter meeting in 2015.

As stated above, we hold the West China Forum for Post-marketing Drug Evaluation and Policy in conjunction with the Chapter meeting. Over 200 participants from academia, clinical practice and industry attended this conference. During this forum, we celebrated the establishment of the ISPOR West China Chapter. The attendees were excited seeing the chapter in western China.

This conference is a national forum to discuss the clinical and health policy on post-marketing drugs. The officials from national and regional centers for adverse drug reaction monitoring, scholars from the medical institutions, and the pharmacists from hospitals shared their views and experiences with the participants on diverse topics, including national drug policy, pharmacoeconomics, post-marketing drug surveillance and use, and outcome research. The audiences were highly excited about having a platform to share the ideas and knowledge on pharmacoeconomics and outcome research.

Membership Development

After the approval of the West China Chapter from ISPOR and West China Hospital, the professionals working on pharmacoeconomics, outcome research, drug monitoring and policy, and pharmaceutical practice in the central and western China – a small proportion from east part as well – were contacted. The professionals from academic institutions, health authorities, pharmaceutical industries, and other organizations in China were introduced to join the chapter. At the end of the year, when the first meeting of core members was held, there were 40 core members from 19 provinces, municipalities and autonomous regions of China. Both senior fellows and young researchers were invited to join the chapter.

Besides the core members, the regular members are also important to the chapter. We are now planning the online registration for the regular members. The registration will help us to promote more colleagues to participate in the study of pharmacoeconomics and
outcomes research and educate the young generations interested in pharmacoeconomics and outcomes research. We anticipate that the online registration be open in 2015.

| Other | N/A |

### Upcoming Activities for ISPOR West China Chapter in 2015

<table>
<thead>
<tr>
<th>Date</th>
<th>Activities</th>
</tr>
</thead>
<tbody>
<tr>
<td>June 2015</td>
<td>The second meeting of the executive office and members</td>
</tr>
<tr>
<td>September 2015</td>
<td>The 2015 West China forum on post-marketing drug evaluation and policy</td>
</tr>
</tbody>
</table>